Drug Treatment of Cholangiocarcinoma
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 5 November 2024 | Viewed by 78
Special Issue Editors
2. Houston Methodist Research Institute, Houston, TX 77030, USA
Interests: transplant oncology; liver cancer; cholangiocarcinoma; targeted therapy; immunotherapy
Special Issues, Collections and Topics in MDPI journals
2. Director of Clinical Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: onco-nephrology; transplant oncology; immunotherapy; immunotherapy toxicity; renal transplant
Special Issue Information
Dear Colleagues,
Cholangiocarcinoma (CGC) is the second most common type of primary liver cancer after hepatocellular carcinoma (HCC), accounting for 10–20% of all primary liver tumors. It is commonly referred to as biliary tree cancer since it emerges anywhere along the biliary tract. It is considered a rare cancer, and approximately 8000 individuals in the United States are diagnosed with it each year. Only a small percentage of cases can be cured by surgical intervention (i.e., liver resection (LR) and liver transplantation (LT)). The first-line chemotherapy regimen of gemcitabine and cisplatin, combined with immunotherapy with durvalumab, has been shown to improve median overall survival. Since the Food and Drug Administration (FDA) approved the isocitrate dehydrogenase (IDH) 1 inhibitor ivosidenib in 2021, there has been a surge in interest in targeted therapy for CCA patients with mutations in fibroblast growth factor receptor (FGFR) 2, neurotrophic receptor tyrosine kinase (NTRK), B-raf kinase (BRAF), and HER2.
This Special Issue will highlight the current state of CCA therapies.
Dr. Abdullah Esmail
Dr. Ala Abudayyeh
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cholangiocarcinoma
- hepatic malignancy
- intrahepatic (iCCA)
- perihilar (pCCA)
- gemcitabine
- cisplatin
- immunotherapy
- durvalumab and distal (dCCA)
